{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:57:49Z","timestamp":1791986269207,"version":"4.4.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T00:00:00Z","timestamp":1549324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s40268-019-0262-3","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T02:03:21Z","timestamp":1549332201000},"page":"15-25","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Inhaled Loxapine for the Management of Acute Agitation in Bipolar Disorder and Schizophrenia: Expert Review and Commentary in an Era of Change"],"prefix":"10.1007","volume":"19","author":[{"given":"Bruno","family":"Pacciardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Calcedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Messer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,5]]},"reference":[{"key":"262_CR1","unstructured":"World Health Organization. Mental disorders. \n                    http:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/mental-disorders\n                    \n                  . Accessed Jun 2018."},{"key":"262_CR2","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.12688\/f1000research.12329.1","volume":"6","author":"JK Rybakowski","year":"2017","unstructured":"Rybakowski JK. Recent advances in the understanding and management of bipolar disorder in adults. F1000Res. 2017;6:2033.","journal-title":"F1000Res"},{"key":"262_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2174\/1570159X14666160606210811","volume":"15","author":"L Tondo","year":"2017","unstructured":"Tondo L, et al. Depression and mania in bipolar disorder. Curr Neuropharmacol. 2017;15:353\u20138.","journal-title":"Curr Neuropharmacol"},{"key":"262_CR4","doi-asserted-by":"publisher","first-page":"659","DOI":"10.5964\/ejop.v12i4.909","volume":"12","author":"W Duarte","year":"2016","unstructured":"Duarte W, et al. The relationship between neurocognitive functioning and occupational functioning in bipolar disorder: a literature review. Eur J Psychol. 2016;12:659\u201378.","journal-title":"Eur J Psychol."},{"key":"262_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.24869\/psyd.2017.108","volume":"29","author":"P Piotrowski","year":"2017","unstructured":"Piotrowski P, et al. Causes of mortality in schizophrenia: a updated review of European studies. Psychiat Danub. 2017;29:108\u201320.","journal-title":"Psychiat Danub."},{"key":"262_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.9758\/cpn.2018.16.1.7","volume":"16","author":"A Tripathi","year":"2018","unstructured":"Tripathi A, et al. Cognitive deficits in schizophrenia: understanding the biological correlates and remediation strategies. Clin Psychopharmacol Neurosci. 2018;16:7\u201317.","journal-title":"Clin Psychopharmacol Neurosci."},{"key":"262_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/15622975.2015.1132007","volume":"17","author":"M Garriga","year":"2016","unstructured":"Garriga M, et al. Assessment and management of agitation in psychiatry: expert consensus. World J Biol Psychiatry. 2016;17:86\u2013128.","journal-title":"World J Biol Psychiatry."},{"issue":"Suppl. 10","key":"262_CR8","first-page":"5","volume":"67","author":"GS Sachs","year":"2006","unstructured":"Sachs GS. A review of agitation in mental illness: burden of illness and underlying pathology. J Clin Psychiatry. 2006;67(Suppl. 10):5\u201312.","journal-title":"J Clin Psychiatry"},{"key":"262_CR9","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000.","edition":"4"},{"key":"262_CR10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1177\/0269881118776738","volume":"32","author":"MX Patel","year":"2018","unstructured":"Patel MX, et al. Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: de-escalation and rapid tranquillisation. J Psychopharmacol. 2018;32:601\u201340.","journal-title":"J Psychopharmacol."},{"key":"262_CR11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/01.pra.0000398410.21374.7d","volume":"17","author":"CS Hankin","year":"2011","unstructured":"Hankin CS, et al. Agitation in the inpatient psychiatric setting: a review of clinical presentation, burden, and treatment. J Psychiatr Pract. 2011;17:170\u201385.","journal-title":"J Psychiatr Pract."},{"key":"262_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fpsyt.2018.00054","volume":"9","author":"J Martinez-Raga","year":"2018","unstructured":"Martinez-Raga J, et al. 1st International Experts\u2019 Meeting on Agitation: conclusions regarding the current and ideal management paradigm of agitation. Front Psychiatry. 2018;9:54.","journal-title":"Front Psychiatry."},{"key":"262_CR13","unstructured":"Allen MH, Currier GW, Hughes DH, Expert Consensus Panel for Behavioral Emergencies, et al. The expert consensus guideline series: treatment of behavioural emergencies. Postgrad Med. 2001;(Spec No):1\u201388."},{"key":"262_CR14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12888-016-0930-6","volume":"16","author":"TR Jorgensen","year":"2016","unstructured":"Jorgensen TR, et al. The effect of the medicine administration route on health-related quality of life: results from a time trade-off survey in patients with bipolar disorder or schizophrenia in 2 Nordic countries. BMC Psychiatry. 2016;16:244.","journal-title":"BMC Psychiatry."},{"key":"262_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/13548506.2017.1323108","volume":"23","author":"TR Jorgensen","year":"2018","unstructured":"Jorgensen TR, et al. Patient preferences for medicine administration for acute agitation: results from an internet-based survey of patients diagnosed with bipolar disorder or schizophrenia in two Nordic countries. Psychol Health Med. 2018;23:30\u20138.","journal-title":"Psychol Health Med."},{"key":"262_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12991-015-0053-3","volume":"14","author":"D Popovic","year":"2015","unstructured":"Popovic D, et al. Revisiting loxapine: a systematic review. Ann Gen Psychiatry. 2015;14:15.","journal-title":"Ann Gen Psychiatry"},{"key":"262_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ijpharm.2010.10.030","volume":"403","author":"K Dinh","year":"2011","unstructured":"Dinh K, et al. In vitro aerosol characterization of Staccato loxapine. Int J Pharm. 2011;403:101\u20138.","journal-title":"Int J Pharm"},{"key":"262_CR18","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.ajem.2005.02.050","volume":"23","author":"CA Marco","year":"2005","unstructured":"Marco CA, Vaughan J. Emergency management of agitation in schizophrenia. Am J Emerg Med. 2005;23:767\u201376.","journal-title":"Am J Emerg Med"},{"key":"262_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2174\/1745017901612010075","volume":"12","author":"L San","year":"2016","unstructured":"San L, et al. State of acute agitation at psychiatric emergencies in Europe: the STAGE study. Clin Pract Epidemiol Ment Health. 2016;12:75\u201386.","journal-title":"Clin Pract Epidemiol Ment Health."},{"key":"262_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0193-953X(02)00029-1","volume":"26","author":"PF Buckley","year":"2003","unstructured":"Buckley PF, et al. Treatment of the psychotic patients who is violent. Psychiatr Clin North Am. 2003;26:231\u201372.","journal-title":"Psychiatr Clin North Am"},{"key":"262_CR21","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1017\/S109285291300014X","volume":"18","author":"SM Stahl","year":"2013","unstructured":"Stahl SM, et al. \u201cMeta-guidelines\u201d for the management of patients with schizophrenia. CNS Spectr. 2013;18:150\u201362.","journal-title":"CNS Spectr"},{"key":"262_CR22","unstructured":"Fountoulakis KN, et al. The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017). Part 3. The clinical guidelines. Int J Neuropsychopharmacol. 2017;20:180\u201395."},{"key":"262_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.tins.2017.10.006","volume":"41","author":"PJ Harrison","year":"2018","unstructured":"Harrison PJ, et al. The emerging neurobiology of bipolar disorder. Trends Neurosci. 2018;41:18\u201330.","journal-title":"Trends Neurosci"},{"key":"262_CR24","unstructured":"Lehman AF et al. Practice guideline for the treatment of patients with schizophrenia. 2nd ed. 2004. \n                    https:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/schizophrenia.pdf\n                    \n                  . Accessed Jun 2018."},{"key":"262_CR25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00406-015-0598-9","volume":"266","author":"J Mielau","year":"2016","unstructured":"Mielau J, et al. Subjective experience of coercion in psychiatric care: a study comparing the attitudes of patients with healthy volunteers towards coercive methods and their justification. Eur Arch Psychiatry Clin Neurosci. 2016;266:337\u201347.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"262_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0883-9417(98)80059-9","volume":"12","author":"WK Mohr","year":"1998","unstructured":"Mohr WK, et al. A restraint on restraints: the need to reconsider the use of restrictive interventions. Arch Psychiatr Nurs. 1998;12:95\u2013106.","journal-title":"Arch Psychiatr Nurs"},{"key":"262_CR27","unstructured":"Bundesverfassungsgericht. Press release no. 62\/2018. Constitutional requirements regarding the use of physical restraints on patients confined under public law in psychiatric hospitals. 2018. \n                    https:\/\/www.bundesverfassungsgericht.de\/SharedDocs\/Pressemitteilungen\/EN\/2018\/bvg18-062.html\n                    \n                  . Accessed 7 Sep 2018."},{"key":"262_CR28","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12888-017-1490-0","volume":"17","author":"E Vieta","year":"2017","unstructured":"Vieta E, et al. Protocol for the management of psychiatric patients with psychomotor agitation. BMC Psychiatry. 2017;17:328.","journal-title":"BMC Psychiatry."},{"key":"262_CR29","unstructured":"United Nations General Assembly. Session 61 Resolution 106. Convention on the rights of persons with disabilities. A\/RES\/61\/106; 2006."},{"issue":"1","key":"262_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.lpm.2014.04.027","volume":"44","author":"M Horn","year":"2015","unstructured":"Horn M, et al. Prise en charge m\u00e9dicamenteuse des agitations aux urgences: recommandations th\u00e9oriques et \u00e9tudes des pratiques. Presse Med. 2015;44(1):20\u20136.","journal-title":"Presse Med"},{"key":"262_CR31","unstructured":"US Food and Drug Administration. Adasuve\u00ae [prescribing information]. 2017. \n                    http:\/\/adasuve.com\/PDF\/AdasuvePI.pdf\n                    \n                  . Accessed Jun 2018."},{"key":"262_CR32","unstructured":"European Medicines Agency. Adasuve\u00ae 9.1\u00a0mg inhalation powder. SmPC. \n                    https:\/\/www.medicines.org.uk\/emc\/medicine\/32246\n                    \n                  . Accessed Jun 2018."},{"issue":"2","key":"262_CR33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/0091270009347866","volume":"50","author":"DA Spyker","year":"2010","unstructured":"Spyker DA, et al. Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J Clin Pharmacol. 2010;50(2):169\u201379.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"262_CR34","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/jcph.502","volume":"55","author":"DA Spyker","year":"2015","unstructured":"Spyker DA, et al. Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens. J Clin Pharmacol. 2015;55(9):985\u201394.","journal-title":"J Clin Pharmacol"},{"key":"262_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1192\/bjp.bp.110.081513","volume":"198","author":"MD Lesem","year":"2011","unstructured":"Lesem MD, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry. 2011;198:1\u201358.","journal-title":"Br J Psychiatry"},{"key":"262_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1399-5618.2011.00975.x","volume":"14","author":"J Kwentis","year":"2012","unstructured":"Kwentis J, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012;14:31\u201340.","journal-title":"Bipolar Disord"},{"key":"262_CR37","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2147\/TCRM.S31484","volume":"9","author":"L Citrome","year":"2013","unstructured":"Citrome L. Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents. Ther Clin Risk Manag. 2013;9:235\u201345.","journal-title":"Ther Clin Risk Manag"},{"key":"262_CR38","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1192\/bjpo.bp.117.005363","volume":"3","author":"S Zeller","year":"2017","unstructured":"Zeller S, et al. Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses. Br J Psych Open. 2017;3:285\u201390.","journal-title":"Br J Psych Open."},{"key":"262_CR39","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1742-1241.2011.02890.x","volume":"66","author":"L Citrome","year":"2012","unstructured":"Citrome L. Inhaled loxapine for agitation revisited: focus on effect sizes from two phase III randomised controlled trials in persons with schizophrenia or bipolar disorder. Int J Clin Pract. 2012;66:318\u201325.","journal-title":"Int J Clin Pract"},{"key":"262_CR40","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12888-017-1291-5","volume":"17","author":"L San","year":"2017","unstructured":"San L, et al. Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. BMC Psychiatry. 2017;17:126.","journal-title":"BMC Psychiatry."},{"key":"262_CR41","first-page":"30073","volume":"18","author":"L San","year":"2018","unstructured":"San L, et al. PLACID study: a randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. Eur Neuropsychopharmacol. 2018;18:30073\u20137.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"262_CR42","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/WNF.0000000000000153","volume":"39","author":"C Roncero","year":"2016","unstructured":"Roncero C, et al. Effectiveness of inhaled loxapine in dual-diagnosis patients: a case series. Clin Neuropharmacol. 2016;39(4):206\u20139.","journal-title":"Clin Neuropharmacol."},{"issue":"6","key":"262_CR43","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/WNF.0000000000000252","volume":"40","author":"C Roncero","year":"2017","unstructured":"Roncero C, et al. Inhaled loxapine for agitation in intoxicated patients: a case series. Clin Neuropharmacol. 2017;40(6):281\u20135.","journal-title":"Clin Neuropharmacol."},{"key":"262_CR44","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1089\/jamp.2013.1114","volume":"27","author":"N Gross","year":"2014","unstructured":"Gross N, et al. Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease: two randomized controlled trials. J Aerosol Med Pulm Drug Dev. 2014;27:478\u201387.","journal-title":"J Aerosol Med Pulm Drug Dev."},{"key":"262_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5811\/westjem.2011.9.6864","volume":"13","author":"JS Richmond","year":"2012","unstructured":"Richmond JS, et al. Verbal de-escalation of the agitated patient: consensus statement of the American Association for Emergency Psychiatry Project BETA De-escalation Workgroup. West J Emerg Med. 2012;13:17\u201325.","journal-title":"West J Emerg Med."},{"key":"262_CR46","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1176\/appi.ps.201400508","volume":"67","author":"F Cots","year":"2016","unstructured":"Cots F, et al. Hospital costs associated with agitation in the acute care setting. Psychiatr Serv. 2016;67:124\u20137.","journal-title":"Psychiatr Serv"},{"key":"262_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12888-015-0417-x","volume":"15","author":"M Rubio-Valera","year":"2015","unstructured":"Rubio-Valera M, et al. Health service use and costs associated with aggressiveness or agitation and containment in adult psychiatric care: a systematic review of the evidence. BMC Psychiatry. 2015;15:35.","journal-title":"BMC Psychiatry."},{"key":"262_CR48","first-page":"325","volume":"26","author":"C Flood","year":"2008","unstructured":"Flood C, et al. Estimating the costs of conflict and containment on adult acute inpatient psychiatric wards. Nurs Econ. 2008;26:325\u201330.","journal-title":"Nurs Econ"},{"key":"262_CR49","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.psiq.2015.04.002","volume":"22","author":"E Garrido","year":"2015","unstructured":"Garrido E, et al. El coste econ\u00f3mico de los procedimientos de contenci\u00f3n mec\u00e1nica de origen psiqui\u00e1trico en Espa\u00f1a. Psiquiatr Biol. 2015;22:12\u20136.","journal-title":"Psiquiatr Biol."},{"key":"262_CR50","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12888-017-1373-4","volume":"17","author":"A Serrano-Blanco","year":"2017","unstructured":"Serrano-Blanco A, et al. In-patient costs of agitation and containment in a mental health catchment area. BMC Psychiatry. 2017;17:212.","journal-title":"BMC Psychiatry."},{"key":"262_CR51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12991-018-0178-2","volume":"17","author":"S Blanthorn-Hazell","year":"2018","unstructured":"Blanthorn-Hazell S, et al. A survey of caregiver burden in those providing informal care for patients with schizophrenia or bipolar disorder with agitation: results from a European study. Ann Gen Psychiatry. 2018;17:8.","journal-title":"Ann Gen Psychiatry"},{"key":"262_CR52","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12888-018-1673-3","volume":"18","author":"J Roberts","year":"2018","unstructured":"Roberts J, et al. Characterizing the experience of agitation in patients with bipolar disorder and schizophrenia. BMC Psychiatry. 2018;18:104.","journal-title":"BMC Psychiatry."},{"key":"262_CR53","doi-asserted-by":"crossref","unstructured":"van Wijngaarden B, et al. Caregiving in schizophrenia: development, internal consistency and reliability of the Involvement Evaluation Questionnaire-European version. EPSILON Study 4. European psychiatric services: inputs linked to outcome domains and needs. Br J Psychiatry. 2000;39:s21\u20137.","DOI":"10.1192\/bjp.177.39.s21"},{"key":"262_CR54","first-page":"182","volume":"29","author":"A Cester-Martinez","year":"2017","unstructured":"Cester-Martinez A, et al. New medical approach to out-of-hospital treatment of psychomotor agitation in psychiatric patients: a report of 14 cases [in Spanish]. Emergencias. 2017;29:182\u20134.","journal-title":"Emergencias"},{"issue":"10","key":"262_CR55","doi-asserted-by":"publisher","first-page":"e020242","DOI":"10.1136\/bmjopen-2017-020242","volume":"8","author":"E Gil","year":"2018","unstructured":"Gil E, Garcia-Alonso F, Boldeanu A, et al. Safety and efficacy of self-administered inhaled loxapine (Adasuve\u00ae) in agitated patients outside the hospital setting: protocol for a phase IV, single-arm, open-label trial. BMJ Open. 2018;8(10):e020242.","journal-title":"BMJ Open"},{"key":"262_CR56","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/S0013-7006(06)76188-7","volume":"32","author":"FR Cousin","year":"2006","unstructured":"Cousin FR, et al. Therapeutics approach of adult patients with acute and chronic psychotic states: REALITE survey [in French]. Enc\u00e9phale. 2006;32:466\u201373.","journal-title":"Enc\u00e9phale"},{"key":"262_CR57","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1176\/appi.ps.51.6.717","volume":"51","author":"GW Currier","year":"2000","unstructured":"Currier GW, Allen MH. Emergency psychiatry: physical and chemical restraint in the psychiatric emergency service. Psychiatr Serv. 2000;51:717\u20139.","journal-title":"Psychiatr Serv"},{"key":"262_CR58","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/j.1742-1241.2010.02380.x","volume":"64","author":"M Hert De","year":"2010","unstructured":"De Hert M, et al. The prevention of deep vein thrombosis in physically restrained patients with schizophrenia. Int J Clin Pract. 2010;64:1109\u201315.","journal-title":"Int J Clin Pract"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-019-0262-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-019-0262-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-019-0262-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T19:06:59Z","timestamp":1580843219000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-019-0262-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,5]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["262"],"URL":"https:\/\/doi.org\/10.1007\/s40268-019-0262-3","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,5]]},"assertion":[{"value":"5 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Bruno Pacciardi has no conflicts of interest that are directly relevant to the content of this article. Alfredo Calcedo has received honoraria for consulting work from Ferrer International. Thomas Messer has received honoraria for consulting work and clinical speeches from Ferrer International. Ferrer International was given the opportunity to check the data used in this manuscript for factual accuracy only.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}